How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?

H. G. Laverty, C. Benson, E. J. Cartwright, M. J. Cross, C. Garland, Timothy R. Hammond, C. Holloway, N. McMahon, J. Milligan, B. K. Park*, Munir Pirmohamed, C. Pollard, J. Radford, N. Roome, P. Sager, S. Singh, Tobias Suter, W. Suter, Andrew W. Trafford, P. G. A. VoldersR. Wallis, Roslyn Weaver, M. York, J. P. Valentin

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

202 Citations (Web of Science)
Original languageEnglish
Pages (from-to)675-693
JournalBritish Journal of Pharmacology
Issue number4
Publication statusPublished - Jun 2011


  • cardiovascular safety liabilities
  • medicines
  • adverse drug reaction
  • adverse event
  • patient safety
  • drug attrition

Cite this